The abstract is read at the publisher; the summary is JClub's.
In 51 pancreatic cancer patients, FOLFIRINOX-linked serum EV proteomics shows coordinated platelet- and coagulation-related protein decreases, including a significant drop in a seven-protein platelet score.
- Why it matters: Longitudinal, minimally invasive biomarkers are needed to track systemic and tumor-associated treatment response in pancreatic ductal adenocarcinoma.
- What they did: Paired pre- and post-treatment serum EVs from 51 patients (25 FOLFIRINOX, 20 gemcitabine-based) were enriched by Mag-Net and profiled by data independent acquisition mass spectrometry; 941 proteins remained after filtering for paired linear models, pathway analyses, and Cox models.
- The result: Across the cohort, 26 EV proteins changed after treatment; FOLFIRINOX showed 32 differential proteins and down-regulated platelet activation/coagulation/hemostasis pathways, while gemcitabine had no proteins meeting the same threshold; higher baseline ITGB1 predicted longer OS (HR 0.112; BH-FDR 0.0063) and greater platelet-score depletion predicted shorter OS (HR 0.56 per unit increase in Δscore; P = 0.030).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.